KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Goodwill & Intangibles for 17 consecutive years, with $196.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill & Intangibles changed 0.0% year-over-year to $196.2 million, compared with a TTM value of $196.2 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $451.5 million, down 8.03% over the prior year.
  • Goodwill & Intangibles was $196.2 million for Q3 2025 at Biomarin Pharmaceutical, roughly flat from $196.2 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $584.9 million in Q4 2021 and bottomed at $196.2 million in Q2 2021.
  • Average Goodwill & Intangibles over 5 years is $373.8 million, with a median of $447.5 million recorded in 2024.
  • The sharpest move saw Goodwill & Intangibles crashed 66.45% in 2022, then surged 150.21% in 2023.
  • Year by year, Goodwill & Intangibles stood at $584.9 million in 2021, then plummeted by 66.45% to $196.2 million in 2022, then soared by 150.21% to $490.9 million in 2023, then decreased by 8.03% to $451.5 million in 2024, then plummeted by 56.54% to $196.2 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for BMRN at $196.2 million in Q3 2025, $196.2 million in Q2 2025, and $443.5 million in Q1 2025.